Trust Signals
This page grades every major claim by evidence type. We cite named trials and real mechanisms. Where the data are weak or absent, we say so. We have no financial interest in recommending one approach over the other. A skeptical clinician should find the reasoning here reproducible.
Key Takeaways
- TRT directly replaces testosterone and has the strongest clinical evidence, including the multi-site Testosterone Trials (TTrials), for improving sexual function, bone density, and mood in hypogonadal men.
- Growth hormone secretagogue peptides (sermorelin, ipamorelin, CJC-1295) work upstream at the pituitary and do not suppress the hypothalamic-pituitary-gonadal (HPG) axis, preserving fertility in a way TRT does not.
- TRT reliably raises erythrocytosis risk at higher doses and suppresses spermatogenesis; peptide risks center on IGF-1 elevation, blood glucose perturbation, and unknown long-term oncology safety.
- Most research peptides sold online have no large human RCTs; many have only rodent or small Phase I data. That does not make them useless, but the confidence ceiling is low.
- Cost, convenience, and goals diverge sharply: generic testosterone cypionate can cost under $50 per month, while compounded peptide protocols typically run $100 to $400 per month with less evidence of benefit.
What Is the Bottom Line on Peptide vs TRT?
For a man with confirmed hypogonadism (morning total testosterone below roughly 300 ng/dL on two readings), TRT has far stronger evidence and is the clinical standard. Peptides are a reasonable adjunct or a lower-risk alternative for men with borderline levels, fertility concerns, or a preference for preserving endogenous hormone production, but the evidence base is thinner and the regulatory status is murkier.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
How Each Works: Mechanism With Numbers
Testosterone Replacement Therapy
TRT delivers exogenous testosterone that binds androgen receptors (AR) throughout the body. Testosterone is converted peripherally by 5-alpha-reductase to dihydrotestosterone (DHT), a higher-affinity AR ligand, and by aromatase (CYP19A1) to estradiol. A typical injection protocol using testosterone cypionate targets trough serum levels of 400 to 700 ng/dL, though many protocols aim higher. Within days of initiating TRT, LH and FSH fall due to negative feedback at the hypothalamus and pituitary. Intratesticular testosterone, which is orders of magnitude higher than serum testosterone, drops substantially, impairing spermatogenesis. This axis suppression is the defining pharmacological fact about TRT.
Peptide Therapies (Growth Hormone Secretagogues)
The most commonly used performance-related peptides are growth hormone releasing hormone (GHRH) analogs and ghrelin mimetics. Sermorelin is a 29-amino-acid truncated fragment of endogenous GHRH (the native peptide is 44 amino acids). CJC-1295 with DAC (drug affinity complex) extends the half-life from minutes to several days by binding albumin. Ipamorelin is a pentapeptide ghrelin receptor (GHS-R1a) agonist with selective GH release and minimal cortisol or prolactin stimulation compared to older secretagogues like GHRP-6.
These peptides act at the pituitary somatotrophs, stimulating pulsatile GH release. GH then stimulates IGF-1 production primarily in the liver. IGF-1 mediates most of the downstream anabolic and lipolytic effects. This entire cascade leaves the HPG axis (which governs testosterone) essentially untouched. Sermorelin has a plasma half-life of roughly 10 to 12 minutes before enzymatic cleavage; CJC-1295 with DAC extends effective activity to 6 to 8 days per published pharmacokinetic data.
What the mechanism does not prove: stimulating GH pulses in a physiologically intact person does not automatically translate to clinically meaningful muscle gain or fat loss. GH secretagogue trials show modest, statistically significant body composition changes in GH-deficient populations; the effect size in eugonadal, non-GH-deficient adults is smaller and less consistent.
Evidence Ledger
| Claim | Best Evidence Type | Named Source or Trial | Effect Direction | Confidence |
|---|---|---|---|---|
| TRT improves sexual function in hypogonadal men | Multiple RCTs, large multi-site trial | Testosterone Trials (TTrials), Snyder et al., NEJM 2016 | Positive | High |
| TRT improves bone mineral density | RCT within TTrials consortium | Snyder et al., JAMA Internal Medicine 2017 | Positive | High |
| TRT raises erythrocytosis risk | RCTs and systematic reviews | Multiple; summarized in Endocrine Society guidelines 2018 | Harm (dose-dependent) | High |
| TRT suppresses spermatogenesis | RCTs (contraceptive trials) and physiology | World Health Organization male contraceptive trials | Harm (reversible in most) | High |
| Sermorelin increases IGF-1 in GH-deficient adults | Small RCTs, Phase II data | Walker et al. and FDA approval data (sermorelin was approved 1997, withdrawn for commercial reasons) | Positive | Moderate |
| Ipamorelin improves body composition in healthy adults | Small human trials, mostly industry-sponsored | Limited; no large independent RCT identified | Possibly positive, small effect | Low |
| CJC-1295 with DAC extends GH pulse duration | Phase I/II human PK data | Jetro et al. pharmacokinetic publication cited in regulatory filings | Positive (PK endpoint) | Moderate |
| BPC-157 promotes tissue healing | Animal studies (rodent) | Multiple Sikiric group publications; no controlled human trial identified | Positive in animal models | Very Low for humans |
| TRT increases cardiovascular risk in men with pre-existing disease | Mixed RCT and observational data | TRAVERSE trial (Lincoff et al., NEJM 2023) showed non-inferiority in low-risk men; earlier signals in higher-risk populations | Neutral in low-risk; uncertain in high-risk | Moderate |
| GH secretagogues elevate fasting glucose | Mechanism and small trial data | GH-induced insulin resistance; consistent with growth hormone physiology | Harm (modest, dose-dependent) | Moderate |
Honest Head-to-Head Table
| Dimension | TRT (testosterone cypionate, IM) | GH Secretagogue Peptides (e.g., ipamorelin/CJC-1295) | Winner |
|---|---|---|---|
| Evidence quality for efficacy | Multiple large RCTs, FDA-approved indication | Small trials, mostly Phase I/II or animal data | TRT |
| Speed of effect | Libido/energy: 3 to 6 weeks | Weeks to months; indirect mechanism | TRT |
| Fertility preservation | Suppresses spermatogenesis; requires HCG or clomiphene co-therapy | HPG axis largely intact; fertility preserved | Peptides |
| HPG axis suppression | Yes, significant | No meaningful suppression | Peptides |
| Regulatory status (USA) | FDA-approved Schedule III controlled substance | Most are unapproved research chemicals; sermorelin was approved but withdrawn commercially | TRT |
| Erythrocytosis risk | Real, dose-dependent, requires hematocrit monitoring | Not a known risk | Peptides |
| Blood glucose effect | Modest improvement in insulin sensitivity with eugonadism restoration | GH secretagogues can raise fasting glucose modestly | TRT (slight edge) |
| Monthly cost (approximate) | $30 to $100 (generic IM; more via telehealth) | $100 to $400 (compounded or research source) | TRT |
| Purity/sourcing certainty | FDA-regulated pharmacy supply chain | Variable; many sources are unregulated | TRT |
| Long-term oncology safety | Prostate monitoring needed; no proven causation of de novo cancer | Unknown; supraphysiologic IGF-1 is a theoretical concern | Neither clear; both need monitoring |
| Addresses confirmed androgen deficiency | Yes, directly | No; GH axis is separate from androgen axis | TRT |
What Most Pages Get Wrong
They treat peptides and TRT as interchangeable alternatives targeting the same problem. They are not. TRT replaces a deficient hormone in one axis. GH secretagogue peptides operate on a completely separate neuroendocrine axis. A man with low testosterone does not have elevated GH secretagogue therapy as a direct fix. The conflation happens because both are associated with "anti-aging" and "performance" marketing, not because the biology overlaps.
They ignore purity risk entirely. Research peptide vendors are not FDA-regulated. Third-party mass spectrometry analyses of commercially available research peptides have found incorrect concentrations, wrong sequences, and in some cases contamination. A vial labeled "ipamorelin 5 mg" from an unregulated supplier may contain a different amount, a partially degraded product, or endotoxins. This is not a hypothetical; it is a sourcing reality that matters for both efficacy and safety.
They present the GH secretagogue-body composition benefit as equivalent to the TRT-hypogonadism benefit. The TTrials showed clinically meaningful effects in a well-defined patient population. The body composition data for secretagogues in non-GH-deficient adults is thinner, with smaller effect sizes. The honest comparison puts TRT ahead for its labeled indication by a significant margin.
They omit TRAVERSE. The 2023 TRAVERSE trial (Lincoff et al., New England Journal of Medicine) enrolled over 5,200 men with hypogonadism and moderate cardiovascular risk and found TRT non-inferior to placebo for major adverse cardiovascular events. This substantially changed the risk calculus that had made many clinicians hesitant. Pages written before 2023 that describe TRT cardiovascular risk as settled harm are outdated.
Safety and Risk Profile
TRT Risks
- Erythrocytosis: The most common laboratory concern. Hematocrit above 54% triggers dose adjustment per Endocrine Society guidelines. Higher with IM injections than transdermal.
- Cardiovascular: The TRAVERSE trial showed non-inferiority in moderate-risk men; higher-risk populations remain a monitoring priority.
- Prostate: TRT does not appear to cause prostate cancer from current evidence but is contraindicated in men with active or suspected prostate cancer.
- Testicular atrophy and HPG suppression: Near-universal with exogenous testosterone; HCG co-administration partially preserves testicular size.
Peptide Risks
- IGF-1 elevation: Supraphysiologic IGF-1 is associated with increased cancer risk in epidemiological data, though causality from therapeutic use is unproven.
- Glucose: GH is counter-regulatory to insulin. Chronic GH secretagogue use can increase fasting glucose, particularly relevant in pre-diabetic men.
- Water retention: Common with GH-stimulating protocols, similar to recombinant GH.
- Unknown long-term safety: No 5 to 10 year controlled human safety dataset exists for most research peptides.
Fertility and the HPG Axis: The Deciding Factor for Many Men
For men who want to preserve fertility, this is the single most important biological distinction. TRT reliably suppresses LH and FSH through negative feedback, reducing sperm production to near-zero in a meaningful proportion of users within 3 to 4 months. Recovery after stopping TRT is not guaranteed and can take over a year. The WHO male contraceptive trials documented this reliably decades ago.
GH secretagogue peptides do not touch the HPG axis. A man using ipamorelin plus CJC-1295 will still have normal LH pulsatility, testicular function, and sperm production. If the goal is optimizing body composition or recovery without compromising fertility, peptides avoid the primary harm of TRT in this domain. This is not a speculative advantage; it is a direct consequence of the mechanism.
Why the Rules of Thumb Exist: The Chemistry
Why peptides must be refrigerated or frozen: Peptide bonds are susceptible to hydrolysis, especially at elevated temperatures. In aqueous solution, the rate of hydrolysis increases substantially with temperature. Lyophilized (freeze-dried) peptides are stable for months at room temperature because there is no water to drive the reaction. Once reconstituted, the peptide should be refrigerated and used within a timeframe specified by the manufacturer, typically 2 to 4 weeks, because hydrolytic and oxidative degradation proceed measurably at refrigerator temperatures and much faster at room temperature. Freezing the reconstituted solution slows but does not stop degradation and risks denaturation with repeated freeze-thaw cycles.
Why you cannot take most peptides orally: The gastrointestinal tract contains peptidases (enzymes including pepsin, trypsin, and chymotrypsin) that cleave peptide bonds rapidly. A 29-amino-acid peptide like sermorelin would be digested into individual amino acids before absorption. Oral bioavailability for most injectable peptides is effectively zero. Claims about oral peptide products delivering the same bioactive molecule are mechanistically implausible unless the product uses a specific encapsulation technology (cyclization, PEGylation, lipid nanoparticle) specifically validated for that compound.
Why TRT forms matter: Testosterone cypionate uses a cyclopentylpropionate ester that delays release after IM injection by increasing lipophilicity, extending the half-life from roughly 2 to 4 hours (unesterified) to roughly 7 to 8 days. This is a simple lipid solubility manipulation, not a receptor effect. Testosterone undecanoate (Aveed) uses a longer chain ester, extending release further, which is why it requires less frequent dosing but carries a risk of pulmonary oil microembolism with IV injection, hence the REMS program.
Operational and Label Literacy
Reading a Peptide COA (Certificate of Analysis)
- Look for HPLC purity above 98% and mass spectrometry (MS) confirmation of the correct molecular weight. Purity by HPLC alone does not confirm the peptide sequence; MS confirmation does.
- Endotoxin testing (LAL test) should be listed. Endotoxins from bacterial contamination cause injection site inflammation and systemic reactions.
- Verify the stated concentration against the vial weight. A "5 mg" vial should contain a lyophilized cake consistent with roughly 5 mg of peptide by weight.
Reconstitution Math
To make a 1 mg/mL solution from a 5 mg vial: add 5 mL of bacteriostatic water. For a 500 mcg dose from that solution, draw 0.5 mL (50 units on a 100-unit insulin syringe). For a 250 mcg dose, draw 0.25 mL (25 units). Always confirm your syringe units match your calculation before injecting.
What a Degraded Peptide Looks Like
A properly reconstituted clear peptide solution should remain colorless to faintly yellow and clear. Cloudiness, visible particles, or a distinctly yellow or brown color suggests contamination or significant degradation. Discard and do not inject. Lyophilized powder should be white and cohesive; a collapsed or discolored cake may indicate improper manufacturing or storage.
Reading a Testosterone Lab Panel
Total testosterone is the starting point, but free testosterone (the unbound, biologically active fraction) matters especially in men with high SHBG. Hematocrit, PSA (baseline and periodically), and LH/FSH should be checked before starting TRT and at appropriate follow-up intervals per Endocrine Society guidelines. A complete metabolic panel is reasonable to assess baseline glucose before initiating GH secretagogue peptides.
Who Should Choose Which?
| Patient Profile | Suggested Direction | Rationale |
|---|---|---|
| Confirmed hypogonadism (total T below 300 ng/dL x2, symptoms present) | TRT, with physician oversight | Strongest evidence; addresses the actual deficiency directly |
| Low-normal testosterone, fertility priority | Clomiphene or HCG, or observation; peptides do not fix testosterone | HPG-stimulating drugs preserve fertility better than TRT; peptides do not raise testosterone |
| Confirmed GH deficiency (adult-onset) | Recombinant GH (Norditropin etc.) by prescription, or GHRH analog by prescription | GH deficiency has an approved treatment pathway; secretagogues are adjunctive or alternative off-label |
| Normal testosterone and GH, seeking performance edge | Neither is strongly evidence-supported; lifestyle optimization has the strongest base | Effect sizes in eugonadal, non-deficient individuals are small and uncertain |
| On TRT, wants to add body composition support | Combination with GH secretagogue is done clinically; requires monitoring | The axes are independent; combining addresses separate biology but compounds cost and monitoring burden |
FAQ
What is the core difference between peptide therapy and TRT?
TRT replaces testosterone directly from an outside source. Peptides such as sermorelin or CJC-1295 stimulate the pituitary to release growth hormone or signal other pathways, working upstream rather than substituting a hormone. TRT suppresses the HPG axis; most peptides leave it largely intact.
Do peptides raise testosterone levels?
Not directly. Some GnRH analog peptides in research settings can stimulate LH release and modestly raise endogenous testosterone, but these are not the peptides typically marketed for performance. Standard growth hormone secretagogues like ipamorelin do not meaningfully raise testosterone.
Which has stronger evidence: peptide therapy or TRT?
TRT has far stronger clinical evidence. Multiple large randomized controlled trials including the Testosterone Trials (TTrials) consortium confirm efficacy for sexual function, bone density, anemia, and mood in hypogonadal men. Most peptide therapies have small or animal-only datasets.
Can you use peptides and TRT together?
Clinicians do combine them, for example using growth hormone secretagogues alongside TRT to address GH decline separately from androgen deficiency. There are no large safety trials of combination protocols, so this remains off-label and requires medical supervision.
Does TRT cause infertility?
TRT suppresses the HPG axis, reducing LH and FSH, which shuts down testicular testosterone production and impairs spermatogenesis. Fertility often recovers after stopping TRT but recovery can take months to over a year and is not guaranteed in all men.
Are peptides legal to buy and use?
It depends on the peptide. FDA-approved peptides like sermorelin are legal by prescription. Many research peptides such as BPC-157 or ipamorelin are sold legally as research chemicals but are not approved for human use. Purchasing for self-administration occupies a legal gray area in the United States.
What are the main risks of TRT?
Erythrocytosis (elevated hematocrit) is the most common dose-dependent risk, occurring in a meaningful minority of patients on injections. Other risks include HPG axis suppression, testicular atrophy, fluid retention, and a possible modest increase in cardiovascular events in men with pre-existing disease.
What are the main risks of peptide therapy?
Growth hormone secretagogues can raise fasting blood glucose and increase IGF-1 above physiological range. Injection site reactions are common. Long-term oncology safety for supraphysiologic IGF-1 is unknown. Purity of unregulated research peptides is a real sourcing risk.
How does cost compare between peptides and TRT?
Generic testosterone cypionate via prescription can cost as little as $30 to $50 per month. Compounded or research peptide protocols typically run $100 to $400 per month depending on the compound and source, not counting monitoring labs.
Which is better for body composition?
For men with confirmed hypogonadism, TRT has the stronger evidence for improving lean mass and reducing fat mass. Growth hormone secretagogues show modest body composition benefits in clinical trials but effects are smaller and less consistent than supraphysiologic GH therapy, which carries its own risks.
Do peptides preserve fertility better than TRT?
Yes, in general. Because most peptides do not suppress the HPG axis, testicular function is largely preserved. GnRH-stimulating protocols are sometimes used specifically as fertility-preserving alternatives to TRT in men with hypogonadism who want children.
How long does it take to see results from TRT vs peptides?
TRT effects on libido and energy typically appear within 3 to 6 weeks. Full body composition changes may take 3 to 6 months. Peptide effects, when present, generally take longer to manifest because they work indirectly through stimulated hormone release rather than direct replacement.
Sources
- Snyder PJ, Bhasin S, Cunningham GR, et al. Effects of Testosterone Treatment in Older Men. New England Journal of Medicine. 2016;374(7):611-624. (TTrials Sexual Function Trial)
- Snyder PJ, Kopperdahl DL, Stephens-Shields AJ, et al. Effect of Testosterone Treatment on Volumetric Bone Density and Strength in Older Men With Low Testosterone. JAMA Internal Medicine. 2017;177(4):471-479.
- Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism. 2018;103(5):1715-1744.
- Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular Safety of Testosterone-Replacement Therapy (TRAVERSE Trial). New England Journal of Medicine. 2023;389(2):107-117.
- World Health Organization Task Force on Methods for the Regulation of Male Fertility. Contraceptive efficacy of testosterone-induced azoospermia in normal men. Lancet. 1990;336(8721):955-959.
- Thorner MO, Vance ML, Evans WS, et al. Physiological and clinical studies of GRF and GH. Recent Progress in Hormone Research. 1986;42:589-640. (GHRH biology)
- Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism. 2006;91(3):799-805.
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561.
- FDA Drug Approval History: Sermorelin Acetate (Geref). FDA website, historical approval records.
- FDA REMS Program: Aveed (testosterone undecanoate injection). FDA Safety Communication.